Exelixis Swings Cash into Share Buybacks While Collaboration Income Takes Off

*

Exelixis’ Q1 2026 filing reads like a financial tightrope act. On the one side, the company’s operating cash flow surged 19 % YoY to $251.8 million, giving it the bandwidth to fund an aggressive share‑repurchase program. On the other, its cash‑and‑equivalents balance shrank 14 % YoY to $1.43 billion, a decline driven almost entirely by the $590.6 million (13.7 million shares) already bought back under the $750 million program authorized in 2024. A second $750 million buy‑back was approved in May 2026, meaning the firm will continue to drain its cash pile even as it faces a tightening reimbursement landscape.

Why the cash burn matters now

The timing is anything but accidental. The Inflation Reduction Act (IRA) has introduced a new tier of Part D and Part B rebates that kick in when a drug’s price growth outpaces inflation. Exelixis’ flagship product, cabozantinib (CABOMETYX), is protected under the IRA’s small‑biotech exception through 2028 and, thanks to annual CMS applications, the company expects that shield to extend to 2030. Still, the filing flags “phased‑in Part D manufacturer discounts (2025‑2031)” and “additional Part B/Part D rebates for price growth above inflation” as material risks. In plain English: the more cabozantinib sells, the more money the government may claw back.

By plowing cash into buybacks now, management is effectively betting that the drug’s market share and pricing power will stay strong enough to offset those rebates. The company’s own guidance leans on “higher unit volumes and a modest increase in average net selling price” to keep product revenue on an upward trajectory. If the IRA’s rebate formulas bite harder than anticipated, the cash cushion that’s being eroded could become a liability.

A revenue mix that’s quietly shifting

Cabozantinib still commands the lion’s share of product revenue – $552.8 million, up 8 % YoY – but the composition of Exelixis’ top line is changing. License revenue, buoyed by an $8.0 million Takeda milestone, jumped 34 % YoY to $56.9 million, and the royalty rate on future Takeda sales was reset to 20 %. More strikingly, collaboration services revenue exploded 252 % YoY after a negative figure the prior year, reflecting the company’s deepening partnerships with Merck, Natera, and other allies.

These partnership dollars are more than a nice‑to‑have side hustle; they are becoming a hedge against the uncertainty surrounding cabozantinib’s U.S. reimbursement. The filing notes that “future cash‑flow generation will depend heavily on CABOMETYX’s ability to maintain market share and reimbursement,” yet the same paragraph highlights that “collaboration income may partially offset cost increases.” In effect, Exelixis is building a second line of defense: a growing stream of royalties and service fees that can soften the blow if payer pressure intensifies.

Cost discipline amid a cash‑outflow sprint

The quarter also shows a modest but meaningful shift in the expense profile. R&D spend fell 5.8 % YoY to $199.9 million, while SG&A rose only 1.8 % to $139.6 million. The net‑income boost to $210.5 million (basic EPS $0.81) reflects both the cost‑containment and the upside from higher non‑product revenue. Yet the cash‑outflow from financing activities surged 55 % YoY to $457.1 million, almost entirely due to the share repurchases.

Analysts will likely ask whether the company can sustain this dual strategy – funding a pipeline that includes the oral MET/VEGF inhibitor zanzalintib (currently under FDA review) and a suite of ADCs and bispecifics – while continuing to return capital to shareholders. The filing’s risk‑factor section offers no new items, but the underlying narrative is clear: the company is walking a fine line between cash generation and cash consumption.

Pipeline progress that could tip the balance

The most promising catalyst on the horizon is zanzalintib. The STELLAR‑303 trial, a head‑to‑head against regorafenib, delivered a statistically significant overall‑survival benefit (HR 0.80, P = 0.0045) and a 20 % risk reduction. An NDA for the zanzalintib‑atezolizumab combo was filed in December 2025, with a PDUFA target of Dec 3 2026. If the FDA grants approval, Exelixis could add a high‑margin, next‑generation product to its portfolio, potentially offsetting any future rebate drag on cabozantinib.

But the pipeline is still early‑stage for many candidates (XL309, XB010, XB628, XB371, XB773). The company plans to advance up to two new development candidates into pre‑clinical work in 2026, a commitment that will require cash. The balance sheet, while still robust at $1.43 billion, is being whittled down by the buyback program – a fact that investors will watch closely as the next FDA decision looms.

What investors should watch

1. Cash runway – With $1.43 billion on hand and $590 million already spent on buybacks, the company has roughly $840 million left for operations, pipeline spend, and any unforeseen rebate hits. The next 12‑month liquidity forecast will be a key barometer.
2. Rebate exposure – Any acceleration in IRA‑driven Part D/Part B rebates could erode margins faster than anticipated, especially if cabozantinib’s price growth exceeds inflation.
3. Zanzalintib’s fate – A positive FDA decision before the end of 2026 could dramatically improve the revenue mix and reduce reliance on cabozantinib.
4. Collaboration momentum – The 252 % jump in collaboration services revenue signals that Exelixis’ partnership model is gaining traction; continued growth here could provide a buffer against payer pressure.
5. Share‑price reaction – The stock slipped 6.2 % on the day of the earnings release, reflecting market nerves about cash depletion despite the upbeat earnings.

In short, Exelixis is betting its future on a three‑pronged play: keep cabozantinib humming, let partnership royalties and services grow, and use the cash it still has to reward shareholders now. Whether that gamble pays off will hinge on how quickly the IRA’s rebate mechanisms bite, and whether zanzalintib can deliver the next wave of growth before the cash runs out.

*